Loading people...
Katie Mangialardi is a Principal at the Autism Impact Fund and an MD Candidate at the Renaissance School of Medicine at Stony Brook University, based in the New York City Metropolitan Area. In her current role, she manages venture capital investments ranging from $100,000 to $5 million across the Seed and Series A stages, targeting biotechnology, diagnostics, and therapeutics. Her investment portfolio features early and growth-stage neurodiversity companies, including Cortica, which previously secured an $80 million venture funding round. Prior to assuming her current professional positions, she worked as a Private Equity Associate at Arsenal Capital Partners and served as an Investment Banking Analyst within the healthcare group at Piper Sandler. Leveraging her background in healthcare finance, Mangialardi currently focuses her dual career on advancing financial and medical solutions for autism, mental health, and complex chronic conditions.
Katie Mangialardi is a distinguished Principal at the Autism Impact Fund, a pioneering organization committed to deploying capital into ventures that create significant positive change for the autism community. In her role, Katie is instrumental in sourcing, evaluating, and executing investments in companies poised to make a tangible difference in areas such as diagnostics, therapeutics, education, employment, and daily living support for individuals on the autism spectrum.
Her investment focus at the Autism Impact Fund is broad yet deeply specialized, targeting innovative solutions across various sectors. This includes cutting edge healthcare technologies, accessible educational platforms, supportive employment initiatives, and services that enhance the quality of life for autistic individuals and their families. Katie seeks out enterprises that not only offer strong financial returns but also demonstrate a clear, measurable social impact, aligning with the fund's dual mandate of financial and social good.
Katie's career background reflects a strong foundation in venture capital and impact investing, often with a particular emphasis on healthcare and technology sectors. Prior to her tenure at the Autism Impact Fund, she honed her expertise in identifying high growth potential companies and guiding them through various stages of development. Her experience spans due diligence, deal structuring, and portfolio management, equipping her with a comprehensive understanding of what it takes for early stage and growth stage companies to succeed and scale their impact. This background has provided her with a unique perspective on how to blend rigorous financial analysis with a deep commitment to social mission.
While specific notable investments are proprietary to the fund's portfolio, Katie's work contributes directly to the Autism Impact Fund's mission of building a robust ecosystem of support for the autism community. Her efforts help to accelerate the development and adoption of solutions that address unmet needs, foster greater inclusion, and empower individuals with autism to thrive. Through her strategic vision and dedication, Katie Mangialardi is a key driver in advancing the Autism Impact Fund's goal of creating a more inclusive and supportive world for neurodiverse individuals.
Katie Mangialardi is a Principal at the Autism Impact Fund, where she focuses on making strategic investments in companies that aim to improve the lives of individuals with autism.
Katie Mangialardi invests in innovative solutions across healthcare, technology, education, employment, and daily living services that benefit the autism community. Her focus is on ventures with both strong financial potential and measurable social impact.
Katie Mangialardi works as a Principal at the Autism Impact Fund, an organization dedicated to investing in companies that create positive change for the autism community.
